Category Archives: Regulations

The EMA and Foreign Data_Part 2

Previously we looked at data from the European Medicines Agency, which showed the increasing role since 2005 that some ‘Rest of the World’ nations were playing in enrolling patients in clinical trials supplying pivotal data for marketing authorisation applications (MAAs) … Continue reading

Posted in EMA, European Union, Regulations | Leave a comment

The EMA and Foreign Data_Part 1

In recent years we have seen an increase in the number of trials conducted for EU marketing authority applications (MAA) in areas other than what was considered to be in the two main European [European Union (EU) / European Economic … Continue reading

Posted in EMA, European Union, Regulations | Leave a comment

MEDICAL DEVICE COMPANIES CAN RELY ON SOUND FOREIGN CLINICAL DATA SAY NEW DRAFT FDA GUIDELINES

New draft guidance has just been issued by the US Food and Drug Administration (FDA), which aims to make it easier for medical device companies to rely on data obtained from clinical studies conducted outside the United States (conveniently termed … Continue reading

Posted in FDA, Regulations | Leave a comment

The reference for writing Clinical Study Report [Clarity and Openness in Reporting: E3-based (CORE)] and the guidance for writing Clinical Study Protocol – a new initiative of the European Medical Writers Association and the American Medical Writers Association_Part 2

Though the CORE (Clarity and Openness in Reporting: E3-based) Reference is planned to be available in the mid-2016, it is very likely that BWG review and analysis will be shared for review at the end of the first quarter of … Continue reading

Posted in Regulations | Leave a comment

The reference for writing Clinical Study Report [Clarity and Openness in Reporting: E3-based (CORE)] and the guidance for writing Clinical Study Protocol – a new initiative of the European Medical Writers Association and the American Medical Writers Association_Part 1

All over the world and across different nations and cultures, the standardisation in managing and providing clinical research is not a dream anymore, but it’s a reality with still growing awareness of the importance of international clarity and harmony in … Continue reading

Posted in Regulations | Leave a comment

The goal: improvement in safety of medicines

As our life is strongly influenced by the fast growth of the pharmaceutical industry, there is an urgent need for control of their products. Safety of drugs available on the market depends on proper reporting procedures of any adverse drug … Continue reading

Posted in EMA, Regulations | Leave a comment

Clinical Trials: A globalized and tech-based future – Part 1

At Clinical Accelerator we are always looking to the future for new innovations and advances in technology. But what will that future be like? In this post I discuss the increasingly globalized clinical trials market and the challenges this poses, … Continue reading

Posted in Regulations | Leave a comment

Clinical trials firm nutraceuticals position

As you know, the emergence of our increasingly health conscious public is driving the growth of the nutraceutical industry. It is one of the fastest-growing industries worldwide (Forbes, 2013) and is already highly profitable. In 2012, Forbes reported that nutrient supplements … Continue reading

Posted in Nutraceuticals, Regulations | Leave a comment

Clinical trials with negative results – to publish or not to publish?

A “finding” – what does it mean? In a clinical trial language a finding is usually referred to a numerical result of an analysis for a specific outcome, for example a relative risk (1). In proper understanding of research it … Continue reading

Posted in Regulations | Leave a comment

FDA inspections produce solid evidence of high quality clinical trial data originating in Central and Eastern Europe

Clinical Accelerator is a clinical CRO with a special focus on Central and Eastern Europe currently operating in 11 countries of the region: Belarus, Estonia, Georgia, Hungary, Latvia, Lithuania, Moldova, Poland, Romania, Russian Federation and Ukraine (listed alphabetically).  The quality … Continue reading

Posted in Central and Eastern Europe, Clinical Accelerator, FDA, Regulations | Leave a comment